Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,629 GBX | -0.67% | -7.78% | +12.33% |
06-08 | US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59 | RE |
06-07 | GSK says FDA Approves Expanded Age Indication For Arexvy, RSV Vaccine For Adults Aged 50-59 At Increased Risk | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.33% | 84.52B | |
+45.82% | 765B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.45% | 248B | |
-0.78% | 219B | |
+11.88% | 216B | |
+5.90% | 164B | |
-0.73% | 162B |
- Stock Market
- Equities
- GSK Stock
- News GSK plc
- Abu Dhabi to Host GSK's Regional Vaccine Hub Under New Health Partnership